Publikationen (38) Publikationen, an denen Forscher/innen teilgenommen haben

2021

  1. AB0771 High Dose Intravenous Methylprednisolone Induces Rapid Improvement of Visual Acuity in Non-Infectious Uveitis of Different Immune Mediated Inflammatory Diseases

    Annals of the Rheumatic Diseases, Vol. 80, Núm. Suppl 1, pp. 1412.1-1412

  2. Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients

    Rheumatology (Oxford, England), Vol. 61, Núm. 1, pp. 299-308

  3. Author Correction: BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis (Scientific Reports, (2021), 11, 1, (11510), 10.1038/s41598-021-91055-z)

    Scientific Reports

  4. BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

  5. Body mass index and disease activity in chronic inflammatory rheumatic diseases: Results of the cardiovascular in rheumatology (CARMA) project

    Journal of Clinical Medicine, Vol. 10, Núm. 3, pp. 1-10

  6. Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry

    Scientific Reports, Vol. 11, Núm. 1

  7. Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach

    Pediatric Rheumatology, Vol. 19, Núm. 1

  8. Combined use of QRISK3 and SCORE as predictors of carotid plaques in patients with rheumatoid arthritis

    Rheumatology (Oxford, England), Vol. 60, Núm. 6, pp. 2801-2807

  9. Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain

    Reumatologia Clinica, Vol. 17, Núm. 5, pp. 245-249

  10. Correction to: Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects (Journal of Human Genetics, (2021), 66, 2, (161-169), 10.1038/s10038-020-0821-z)

    Journal of Human Genetics

  11. Cost-Effectiveness of Therapeutic Drug Monitoring-Guided Adalimumab Therapy in Rheumatic Diseases: A Prospective, Pragmatic Trial

    Rheumatology and Therapy, Vol. 8, Núm. 3, pp. 1323-1339

  12. Cranial and extracranial giant cell arteritis do not have different HLA-DRB1 and HLA-B association in Caucasian individuals

    Arthritis Research and Therapy

  13. Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk

    Arthritis Research and Therapy, Vol. 23, Núm. 1

  14. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563

  15. Evaluation of the collaboration between Primary and Hospital Care in order to improve inappropriate prescription

    Journal of Healthcare Quality Research, Vol. 36, Núm. 2, pp. 91-97

  16. Flare rate thresholds for patient assessment of disease activity states in Gout

    Journal of Rheumatology, Vol. 48, Núm. 2, pp. 293-298

  17. HLA association with the susceptibility to anti-synthetase syndrome

    Joint Bone Spine, Vol. 88, Núm. 3

  18. IgG4-related lung disease. A case report

    Medicina Clinica

  19. Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey

    Joint Bone Spine, Vol. 88, Núm. 4

  20. Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER)

    Rheumatology (Oxford, England), Vol. 60, Núm. 4, pp. 1793-1803